Development, Statistical Optimization and Characterization of Fluvastatin Loaded Solid Lipid Nanoparticles: A 3<sup>2</sup> Factorial Design Approach

The purpose of the present research work was to design, optimize, and evaluate fluvastatin-loaded solid lipid nanoparticles (FLV-SLNPs) using 3<sup>2</sup> factorial design for enhancing the bioavailability. Fluvastatin has several disadvantages, including the low solubility and substant...

Full description

Saved in:
Bibliographic Details
Main Authors: Afzal Haq Asif (Author), Prasanna Kumar Desu (Author), Rajasekhar Reddy Alavala (Author), Gudhanti Siva Naga Koteswara Rao (Author), Nagaraja Sreeharsha (Author), Girish Meravanige (Author)
Format: Book
Published: MDPI AG, 2022-03-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_cbbaba77d62b4c83ad9b12a9ec9f8bb9
042 |a dc 
100 1 0 |a Afzal Haq Asif  |e author 
700 1 0 |a Prasanna Kumar Desu  |e author 
700 1 0 |a Rajasekhar Reddy Alavala  |e author 
700 1 0 |a Gudhanti Siva Naga Koteswara Rao  |e author 
700 1 0 |a Nagaraja Sreeharsha  |e author 
700 1 0 |a Girish Meravanige  |e author 
245 0 0 |a Development, Statistical Optimization and Characterization of Fluvastatin Loaded Solid Lipid Nanoparticles: A 3<sup>2</sup> Factorial Design Approach 
260 |b MDPI AG,   |c 2022-03-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics14030584 
500 |a 1999-4923 
520 |a The purpose of the present research work was to design, optimize, and evaluate fluvastatin-loaded solid lipid nanoparticles (FLV-SLNPs) using 3<sup>2</sup> factorial design for enhancing the bioavailability. Fluvastatin has several disadvantages, including the low solubility and substantial first-pass metabolism resulting in a low (30%) bioavailability and a short elimination half-life. FLV-SLNPs were prepared using the nano-emulsion technique. For the optimization of the FLV-SLNPs, a total of nine formulations were prepared by varying two independent factors at three levels, using full factorial design. In this design, lipid (A) and surfactant (B) concentrations were chosen as independent factors, whereas entrapment efficiency (Y1) and in-vitro drug release (Y2) were selected as the dependent variables. Additionally, the prepared SLNPs were characterized for X-ray diffraction, Fourier transform-infrared spectroscopy, and differential scanning calorimetry. These studies revealed that there were no interactions between the drug and the selected excipients and the selected formulation components are compatible with the drug. Pharmacokinetic studies in rats confirmed significant improvement in AUC and MRT of SLNPs in comparison with the pure drug indicating the enhanced bioavailability of SLNPs. This study provides a proof-of-concept for the fact that SLNPs can be effectively developed via experimental factorial design, which requires relatively minimal experimentation. 
546 |a EN 
690 |a fluvastatin sodium 
690 |a 3<sup>2</sup> factorial design 
690 |a particle size 
690 |a in vitro drug release 
690 |a contour plots 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 14, Iss 3, p 584 (2022) 
787 0 |n https://www.mdpi.com/1999-4923/14/3/584 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/cbbaba77d62b4c83ad9b12a9ec9f8bb9  |z Connect to this object online.